NAV — Navco Pharmaceuticals Share Price
Last trade - 00:00- CA$1.43m
- CA$1.51m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.46 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -952.51% | ||
| Return on Equity | -2660.2% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Navco Pharmaceuticals Inc. is a Canada-based company. The Company is engaged in developing and commercializing products to protect against viruses, bacteria, and infectious diseases. It manufactures and researches nanotechnology products and materials using Computerized Nano-meter Algorithms (CNA). The Company's pipeline of applications is tailored to defend against microorganisms such as viruses, bacteria, fungi, and genetic manipulation tools such as clustered regularly interspaced short palindromic repeats (CRISPR). Its target markets include human health and personal skin care, household and institutional products and veterinary health. It offers multiple main product lines, namely, an aerosol spray, hand sanitizer, hand cream, and nano BioGuard-Silver. It also offers sublingual strips (the MunoStrips) infused with immune-boosting compounds to help maintain immune function and help support the body’s metabolism.
Directors
- Last Annual
- September 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- April 21st, 2018
- Public Since
- November 5th, 2018
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 57,069,541
- Address
- 1090 West Georgia Street, #600, Vancouver, V6E 3V7
- Web
- Phone
- +1 7785496714
- Auditors
- Dale Matheson Carr-Hilton LaBonte LLP
Upcoming Events for NAV
Similar to NAV
MiniLuxe Holding
TSX Venture Exchange
FAQ
As of Today at 22:15 UTC, shares in Navco Pharmaceuticals are trading at CA$0.05. This share price information is delayed by 15 minutes.
Shares in Navco Pharmaceuticals last closed at CA$0.05 and the price had moved by -9.09% over the past 365 days. In terms of relative price strength the Navco Pharmaceuticals share price has underperformed the Toronto Stock Exchange 300 Composite Index by -18.1% over the past year.
There is no consensus recommendation for this security.
Navco Pharmaceuticals does not currently pay a dividend.
Navco Pharmaceuticals does not currently pay a dividend.
Navco Pharmaceuticals does not currently pay a dividend.
To buy shares in Navco Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.05, shares in Navco Pharmaceuticals had a market capitalisation of CA$2.85m.
Here are the trading details for Navco Pharmaceuticals:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: NAV
Based on an overall assessment of its quality, value and momentum Navco Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Navco Pharmaceuticals. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +95%.
As of the last closing price of CA$0.05, shares in Navco Pharmaceuticals were trading -19.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Navco Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Navco Pharmaceuticals' directors